http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012103502-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate | 2010-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012103502-A |
| titleOfInvention | HYR1 AS TARGET FOR ACTIVE AND PASSIVE IMMUNIZATION AGAINST Candida |
| abstract | 1. A vaccine comprising a polypeptide ideally identical to a substantially fragment of the HYR1.2 polypeptide. The vaccine according to claim 1, characterized in that the HYR1 polypeptide is 3. The vaccine according to claim 1, characterized in that it further comprises an adjuvant. The vaccine according to claim 1, characterized in that the HYR1 polypeptide fragment is expressed in a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis. The vaccine according to claim 1, characterized in that the fragment consists of the N-terminal region of the fragment of the HYR1.6 polypeptide. The vaccine according to claim 4, characterized in that the fragment is 7. The vaccine according to claim 6, characterized in that the fragment is a fusion polypeptide. The vaccine according to claim 7, characterized in that the fragment is fused to a heterologous leader sequence. The vaccine according to claim 7, characterized in that the fragment is fused with a label or linker sequence. The vaccine of claim 10, wherein the label is the histidine end. The vaccine according to claim 1, characterized in that the fragment is obtained from transformed cells. The vaccine according to claim 11, characterized in that the transformed cells are Saccharomyces cerevisae cells. A method for treating or preventing a candida infection, comprising administering an immunogenic amount of a vaccine according to any one of claims 1-12.14. The method of claim 13, wherein the candida infection is disseminated candidiasis. The method of claim 13, wherein the administration comprises active immunization, passive immunization, or a combination thereof. A method for treating or preventing candida infection, comprising administering an effective amount of an isolated polypeptide identical to |
| priorityDate | 2009-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6274 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550758 |
Total number of triples: 19.